Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Immunomodulatory Drugs (IMiDs)
100%
Clinically Significant
100%
Multiple Myeloma
100%
Credentialing
100%
Genetically Engineered
100%
Mouse Model
100%
Vk*MYC
40%
Cereblon
20%
Transgenic Mice
20%
Mechanism of Action
20%
Ex Vivo System
20%
Immune System
20%
Relapsed/refractory multiple Myeloma
20%
Clinical Practice
20%
Clinical Application
20%
Transgenic Mouse Model
20%
Amino Acid Sequence
20%
Murine Cells
20%
Lenalidomide
20%
Regulatory Elements
20%
Pomalidomide
20%
Relapsed/refractory
20%
Tumor
20%
Ligand-binding Domain
20%
Multiple Myeloma Patients
20%
Thalidomide
10%
Hematological Malignancies
10%
Newly Diagnosed
10%
Immune Modulation
10%
Malignancy
10%
Thal
10%
Immunology and Microbiology
Mouse Model
100%
Multiple Myeloma
100%
Transgenic Mouse
58%
Pomalidomide
29%
Vertebral Column
29%
Lenalidomide
29%
Amino Acid Sequence
29%
Immune System
29%
Thalidomide
12%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse Model
100%
Multiple Myeloma
100%
Transgenic Mouse
58%
Pomalidomide
29%
Amino Acid
29%
Lenalidomide
29%
Neoplasm
29%
Hematologic Malignancy
12%
Thalidomide
12%